

Remarks

Rejection of Claims 1-11 Under 35 U.S.C. § 112 ¶1

The Advisory Action maintains the enablement rejection of claims 1-11. Applicants respectfully traverse the rejection.

On page 3, the Advisory Action contends that Applicants have not shown “a connection between altered levels of FRPL1 polypeptide or mRNA and any cardiovascular disease or condition, or indeed, any disease condition.” To advance prosecution, the pending claims have been amended to recite cardiovascular diseases, COPD, asthma, and genito-urolological disorders. The references listed in the accompanying Information Disclosure Statement support the specification’s disclosure that the FRPL1 ligand lipoxin A4 is involved in cardiovascular diseases (Levy)¹, respiratory diseases (*e.g.*, COPD, asthma; Wu), and genito-urolological disorders (*e.g.*, renal disease; Rodgers).²

Please withdraw the rejection.

Respectfully submitted,
BANNER & WITCOFF, LTD.

/Lisa M. Hemmendinger/

Dated: May 10, 2007

By: _____
Lisa M. Hemmendinger
Registration No. 42,653

Customer No. 22907

¹ The “ALX” receptor is the same receptor as the FRPL1 receptor described in the specification (SEQ ID NO:2). See the accompanying BLAST alignment and, *e.g.*, NP_001453.

² The Patent Office essentially doubts the specification’s assertion of the recited receptor’s utility. Use of post-filing date evidence is appropriate to rebut this assertion. See *In re Langer*, 503 F.2d 1380, 1391, 183 U.S.P.Q. 288, 297 (C.C.P.A. 1974); *In re Marzocchi*, 439 F.2d 220, 223, 169 U.S.P.Q. 367, 370 n. 4 (C.C.P.A. 1971).